|
2021 Journal Article Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w)Burgess, M., Chen, Y. C.E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2021). Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w). Oncogene, 40 (6), 1203-1203. doi: 10.1038/s41388-020-01619-y |
|
2021 Journal Article SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patientsChen, Yu-Chen Enya, Burgess, Melinda, Mapp, Sally, Mollee, Peter, Gill, Devinder, Blumenthal, Antje and Saunders, Nicholas A. (2021). SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients. Frontiers in Immunology, 11 610523, 1-12. doi: 10.3389/fimmu.2020.610523 |
|
2021 Journal Article Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trialPerrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, van Rampelbergh, Rian, Uhlar, Clarissa M., Wang, Jianping, Kobos, Rachel, Gries, Katharine S., Fastenau, John and Weisel, Katja (2021). Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial. Journal of Clinical Oncology, 39 (3), 227-237. doi: 10.1200/JCO.20.01370 |
|
2021 Journal Article A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphomaTobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866 |
|
2021 Journal Article Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein ReportingSmith, Joel D, Wijeratne, Nilika, Schneider, Hans G, de Malmanche, Theo, Hissaria, Pravin, Toit, Stephen Du, Chiu, Weldon, Boyder, Conchita, Morison, Ian M, Tseng, Anfernee, Glegg, Kaye, Wienholt, Louise, Mollee, Peter and on behalf of the AACB/RCPA Monoclonal Gammopathy Working Party (2021). Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting. Clinical Biochemist Reviews, 42 (1), 11-16. doi: 10.33176/AACB-21-00001 |
|
2021 Journal Article The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemiaMurali, Aarya, Cross, Donna and Mollee, Peter (2021). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia. Blood Cancer Journal, 11 (1) 6, 6. doi: 10.1038/s41408-020-00401-3 |
|
2021 Journal Article The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograftRees, Matthew J., Mollee, Peter, Ng, Jun Yen, Murton, Alex, Gonsalves, Jose Filipe, Panigrahi, Ashish, Beer, Hayley, Loh, Joanna, Nguyen, Philip, Hunt, Sam, Jina, Hayden, Wayte, Rebecca, Sutrave, Gaurav, Tan, Jocelyn, Abeyakoon, Chathuri, Chee, Ashlyn, Augustson, Bradley, Kalro, Akash, Lee, Cindy, Agrawal, Shivam, Churilov, Leonid, Chua, Chong Chyn, Lim, Andrew Boon Ming, Zantomio, Daniela and Grigg, Andrew (2021). The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. Bone Marrow Transplantation, 56 (9), 2152-2159. doi: 10.1038/s41409-021-01300-2 |
|
2020 Journal Article Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devicesEllis, Marc L., Okano, Satomi, McCann, Andrew, McDowall, Angela, Van Kuilenburg, Rosita, McCarthy, Alexandra L., Joubert, Warren, Harper, John, Jones, Mark and Mollee, Peter (2020). Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Internal Medicine Journal, 50 (12), 1475-1482. doi: 10.1111/imj.14780 |
|
2020 Conference Publication Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor StudyLandgren, Ola, Weisel, Katja, Dachs, Laura Rosinol, Moreau, Philippe, Turgut, Mehmet, Hajek, Roman, Mollee, Peter, Kim, Jin Seok, Zhang, Jianqi, Go, Ning, Morris, Christopher L. and Usmani, Saad Z. (2020). Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-141291 |
|
2020 Conference Publication Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda StudySanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C., Jaccard, Arnaud, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S., Fastenau, John, NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y., Tromp, Brenda, Weiss, Brendan M. ... Wechalekar, Ashutosh D. (2020). Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-139438 |
|
2020 Conference Publication A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphomaTobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590 |
|
2020 Conference Publication Management and outcomes of testicular lymphoma in the rituximab era at an Australian tertiary centreMurali, Aarya, Boyle, Stephen, Mollee, Peter and Hapgood, Greg (2020). Management and outcomes of testicular lymphoma in the rituximab era at an Australian tertiary centre. 62nd ASH Annual Meeting, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-138440 |
|
2020 Conference Publication The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemiaMurali, Aarya, Cross, Donna and Mollee, Peter (2020). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemia. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. AMSTERDAM: American Society of Hematology. doi: 10.1182/blood-2020-140966 |
|
2020 Conference Publication The role of whole body STIR MRI in assessing first biochemical relapse in patients with myelomaRowland, James and Mollee, Peter (2020). The role of whole body STIR MRI in assessing first biochemical relapse in patients with myeloma. 62nd ASH Annual Meeting, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-139194 |
|
2020 Conference Publication Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from AndromedaComenzo, Raymond L., Kastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Sanchorawala, Vaishali, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Dimopoulos, Meletios A., NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y. ... Merlini, Giampaolo (2020). Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-137582 |
|
2020 Conference Publication Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late RelapseWeisel, Katja, Geils, George F., Karlin, Lionel, Mollee, Peter, Chung, Tae-Hoon, Min, Chang-Ki, Sunami, Kazutaka, Goldrick, Amanda, Fang, Belle, Fowler, Jessica and Mateos, Maria-Victoria (2020). Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-133908 |
|
2020 Conference Publication The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Ho, Phoebe Joy, Moore, Elizabeth M., Wellard, Cameron, Quach, Hang, Blacklock, Hilary, Harrison, Simon J., McDonald, Emma-Jane, McQuilten, Zoe, Wood, Erica M., Mollee, Peter and Spencer, Andrew (2020). The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-141511 |
|
2020 Conference Publication Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma AllianceBoyle, Stephen, Tobin, Joshua W. D., Perram, Jacinta, Hamad, Nada, Barraclough, Allison, Singaraveloo, Lydia, Han, Min-Hi, Blennerhassett, Richard, Nelson, Niles Elizabeth, Johnston, Anna, Talaulikar, Dipti, Karpe, Krishna, Bhattacharyya, Abir, Cheah, Chan Yoon, Subramoniapillai, Elango, Bokhari, Waqas, Lee, Cindy, Hawkes, Eliza A., Gullapalli, Veena, Jabbour, Andrew, Strasser, Simone, Chadban, Steve, Brown, Christina, Mollee, Peter and Hapgood, Greg (2020). Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-140665 |
|
2020 Conference Publication An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx StudyNicol, Jennifer L., Hill, Michelle M., Cunningham, Brent, Nunan, Elizabeth, Woodrow, Carmel, Keating, Eliza, Adlard, Kirsten, Smith, Michelle, Mollee, Peter, Weber, Nicholas, Nicol, Andrew J. and Skinner, Tina L. (2020). An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx Study. COSA's 47th Annual Scientific Meeting, Quality and Safety, Implementation Science, Cardio-Oncology, Virtual, 11–13 November 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13499 |
|
2020 Journal Article Physical activity in people with multiple myeloma: associated factors and exercise program preferencesNicol, Jennifer L., Woodrow, Carmel, Burton, Nicola W., Mollee, Peter, Nicol, Andrew J., Hill, Michelle M. and Skinner, Tina L. (2020). Physical activity in people with multiple myeloma: associated factors and exercise program preferences. Journal of Clinical Medicine, 9 (10) 3277, 3277-11. doi: 10.3390/jcm9103277 |
